Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

This study will provide efficacy and safety data of the secukinumab pre-filled syringe (PFS) for subcutaneous self-administration in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α agents.

Key facts

Study ID
NCT01770379
Run by
Novartis Pharmaceuticals
People needed
242
Starts
2012-10-01
Expected to finish
2015-05-01
Last updated by the study team
2016-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.